CClinicalTrials.gg
Sign In
Active, not recruitingNCT05359016Updated May 22, 2026

Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique

An interventional study of HPV testing of women for cervical cancer screening in Cervical Cancer, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to female participants aged 30 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Dec 2020, registered Apr 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
9,014
Allocation
Not applicable
Ages
30 Years to 49 Years
Sex
Female
01

Study summary

The goal of this operational research study is to develop, implement and test integrated CCS\&PT and voluntary FP service delivery models to evaluate whether integrated service delivery can optimize uptake and health impact of both services. The study objectives and learning questions are listed below, along with key outcomes that will be measured.

Read the detailed description

Objectives:

The study objectives are outlined below:

  1. To quantify the health impact of CCS\&PT on the uptake of voluntary FP services.
  2. To quantify the health impact of voluntary FP on the uptake of CCS\&PT services.
  3. To determine which promotional strategies are most effective to increase uptake of CCS\&PT services.
  4. To identify cost to deliver high quality CCS\&PT services integrated into existing voluntary FP programs.
  5. To determine client and provider acceptability of integrated CCS\&PT and voluntary FP services using new screen and treat technologies.
02

Conditions studied

  • Cervical Cancer
03

In context

Uterine Cervical Neoplasms

1,879 studies on the registry are indexed under Uterine Cervical Neoplasms; 565 are open to participants now.

This study's planned enrollment of 9,014 is above the median of 100 across 1,375 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women 30 - 49 years or all women living with HIV
  • Not currently pregnant
  • Patients with a cervix (women who have undergone a total hysterectomy with removal of the cervix are not eligible)
  • Living in Maputo or Gaza
  • Willing and able to provide informed consent for services.

Exclusion criteria

Exclusion Criteria:

  • Not meeting the inclusion criteria
  • Physical or mental impairment that inhibits participation in the study
  • Pregnant women
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9,014 participants (estimated)

Study arms

  • Experimental
    HPV testing of women for cervical cancer screening

    Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.

    Behavioral: HPV testing of women for cervical cancer screening

Interventions

  • BehavioralHPV testing of women for cervical cancer screening

    Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.

06

What researchers measure

Primary outcomes

  1. Number of women who will undergo Cervical Cancer Screening by HPV testing

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05359016
Lead sponsor
M.D. Anderson Cancer Center
Collaborators
Population Services International, Eduardo Mondlane University, William Marsh Rice University
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Dec 22, 2020
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Kathleen Schmeler, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uterine Cervical Neoplasms→

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion